{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:16:38Z","timestamp":1707524198320},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,25]]},"DOI":"10.7759\/cureus.11162","type":"journal-article","created":{"date-parts":[[2020,10,25]],"date-time":"2020-10-25T22:32:58Z","timestamp":1603665178000},"source":"Crossref","is-referenced-by-count":0,"title":["A Review of Interstitial Pneumonitis Caused by Elotuzumab Through Case Discussions and Academic Writings"],"prefix":"10.7759","author":[{"given":"Ghulam","family":"Ghous","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hafiz Muhammad Hassan","family":"Shoukat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahid Ijaz","family":"Tarar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Usman","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0969-4","article-title":"Elotuzumab: a review in relapsed and\/or refractory multiple myeloma","volume":"78","author":"Lamb YN","year":"2018","unstructured":"Lamb YN. Elotuzumab: a review in relapsed and\/or refractory multiple myeloma. Drugs. 2018, 78:1481-1488. 10.1007\/s40265-018-0969-4","journal-title":"Drugs"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2018.1456331","article-title":"Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy","volume":"5","author":"Zamagni E","year":"2018","unstructured":"Zamagni E, Tacchetti P, Pantani L, Cavo M. Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy. Expert Rev Hematol. 2018, 5:423-435. 10.1080\/17474086.2018.1456331","journal-title":"Expert Rev Hematol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S174640","article-title":"Update on elotuzumab for the treatment of relapsed\/refractory multiple myeloma: patients' selection and perspective","volume":"12","author":"Trudel S","year":"2019","unstructured":"Trudel S, Moreau P, Touzeau C. Update on elotuzumab for the treatment of relapsed\/refractory multiple myeloma: patients' selection and perspective. Onco Targets Ther. 2019, 12:5813-5822. 10.2147\/OTT.S174640","journal-title":"Onco Targets Ther"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2020.1740084","article-title":"Monoclonal antibodies in relapsed\/refractory myeloma: updated evidence from clinical trials, real-life studies, and meta-analyses","volume":"13","author":"Musto P","year":"2020","unstructured":"Musto P, La Rocca F. Monoclonal antibodies in relapsed\/refractory myeloma: updated evidence from clinical trials, real-life studies, and meta-analyses. Expert Rev Hematol. 2020, 13:331-349. 10.1080\/17474086.2020.1740084","journal-title":"Expert Rev Hematol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial S","year":"2015","unstructured":"Lonial S, Dimopoulos M, Palumbo A, et al.. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015, 373:621-31. 10.1056\/NEJMoa1505654","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma","volume":"11","author":"Dimopoulos MA","year":"2018","unstructured":"Dimopoulos MA, Dytfeld D, Grosicki S, et al.. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med. 2018, 11:1811-1822. 10.1056\/NEJMoa1805762","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-360552","article-title":"A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma","volume":"120","author":"Zonder JA","year":"2012","unstructured":"Zonder JA, Mohrbacher AF, Singhal S, et al.. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood. 2012, 120:552-9. 10.1182\/blood-2011-06-360552","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyy049","article-title":"Elotuzumab-induced interstitial lung disease: the first case report","volume":"48","author":"Tanaka T","year":"2018","unstructured":"Tanaka T, Saito Y, Kokuho N, et al.. Elotuzumab-induced interstitial lung disease: the first case report. Jpn J Clin Oncol. 2018, 48:491-494. 10.1093\/jjco\/hyy049","journal-title":"Jpn J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.22135","article-title":"Lenalidomide-associated pneumonitis in patients with plasma cell dyscrasias","volume":"86","author":"Zagouri F","year":"2011","unstructured":"Zagouri F, Roussou M, Kastritis E, et al.. Lenalidomide-associated pneumonitis in patients with plasma cell dyscrasias.  Am J Hematol. 2011, 86:882-4. 10.1002\/ajh.22135","journal-title":"Am J Hematol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.51.6651","article-title":"Drug-induced interstitial pneumonitis due to low-dose lenalidomide","volume":"51","author":"Kunimasa K","year":"2012","unstructured":"Kunimasa K, Ueda T, Arita M, Maeda T, Hotta M, Ishida T. Drug-induced interstitial pneumonitis due to low-dose lenalidomide. Intern Med. 2012, 51:1081-5. 10.2169\/internalmedicine.51.6651","journal-title":"Intern Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/rcr2.233","article-title":"Lenalidomide-induced eosinophilic pneumonia","volume":"48","author":"Toma A","year":"2018","unstructured":"Toma A, Rapoport AP, Burke A, Sachdeva A. Lenalidomide-induced eosinophilic pneumonia. Respirol Case Rep.. 2018, 48:491-494. 10.1002\/rcr2.233","journal-title":"Respirol Case Rep."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0000000000000532","article-title":"Pomalidomide-induced pulmonary toxicity in multiple myeloma","volume":"350","author":"Modi D","year":"2015","unstructured":"Modi D, Mamdani H, Vettese T. Pomalidomide-induced pulmonary toxicity in multiple myeloma. Am J Med Sci. 2015, 350:241-2. 10.1097\/MAJ.0000000000000532","journal-title":"Am J Med Sci"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-2082","article-title":"Acute lung toxicity related to pomalidomide","volume":"140","author":"Geyer HL","year":"2011","unstructured":"Geyer HL, Viggiano RW, Lacy MQ, et al.. Acute lung toxicity related to pomalidomide. Chest. 2011, 140:529-533. 10.1378\/chest.10-2082","journal-title":"Chest"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.18.0244","article-title":"Pulmonary toxicity associated with pomalidomide","volume":"11","author":"Gajic S","unstructured":"Gajic S, Callahan EC, Brown JK, Elicker B, Ley B, Blanc PD. Pulmonary toxicity associated with pomalidomide. Int J Tuberc Lung Dis. 11:1383-1386. 10.5588\/ijtld.18.0244","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma","volume":"14","author":"Hsi ED","year":"2008","unstructured":"Hsi ED, Steinle R, Balasa B, et al.. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008, 14:2775-84. 10.1158\/1078-0432.CCR-07-4246","journal-title":"Clin Cancer Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200133","article-title":"Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment","volume":"2","author":"Bienvenu J","year":"2001","unstructured":"Bienvenu J, Chvetzoff R, Salles G, et al.. Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment. Hematol J. 2001, 2:378-84. 10.1038\/sj.thj.6200133","journal-title":"Hematol J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-014-1610-3","article-title":"Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-\u03b1 pathways","volume":"64","author":"Balasa B","year":"2015","unstructured":"Balasa B, Yun R, Belmar NA, et al.. Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-\u03b1 pathways. Cancer Immunol Immunother. 2015, 64:61-73. 10.1007\/s00262-014-1610-3","journal-title":"Cancer Immunol Immunother"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/43697-a-review-of-interstitial-pneumonitis-caused-by-elotuzumab-through-case-discussions-and-academic-writings","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:19:05Z","timestamp":1707506345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/43697-a-review-of-interstitial-pneumonitis-caused-by-elotuzumab-through-case-discussions-and-academic-writings"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,25]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.11162","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10,25]]}}}